Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals, Inc. (AMRX) has filed an automatic shelf registration statement on Form S-3ASR covering the resale, from time to time, of up to 28,942,098 shares of its Class A common stock by certain selling stockholders. These shares were issued as part of the equity consideration in Amneal’s acquisition of Kashiv BioSciences, LLC completed on August 10, 2026, alongside $375,000,000 in cash consideration. The cash portion was funded in part by a $350,000,000 incremental term loan, and the Kashiv sellers may receive up to an additional $350,000,000 in contingent milestone payments plus potential royalties. Amneal states it will not receive any proceeds from sales by the selling stockholders.
Amneal Pharmaceuticals, Inc. (AMRX) insider Andrew S. Boyer, an Executive Vice President, reported a bona fide gift of 80,000 shares of Class A Common Stock on September 1, 2026. The gift was made to a trust for the benefit of certain family members, and Boyer is not the trustee. Following this transfer, he reports 193,646 shares of direct holdings. No Rule 10b5-1 trading plan is reported for this transaction.
Amneal Pharmaceuticals, Inc. (AMRX) reported that Executive Vice President Andrew S. Boyer made a bona fide gift of 152,426 shares of Class A Common Stock on 2026-08-21. The shares were gifted to a trust for the benefit of certain family members, where Boyer does not serve as trustee. Following this transfer, Boyer’s reported direct holdings are 273,646 shares of Class A Common Stock.
Amneal Pharmaceuticals director John Kiely reported two transactions in Class A Common Stock on 2026-08-13. He sold 50,000 shares at a weighted average price of $17.64 per share in multiple trades within a $17.26–$17.88 range, and separately donated 10,000 shares as a charitable gift to a donor advised fund.
Amneal Pharmaceuticals, Inc. Executive Vice President Nikita Shah reported a sale of 146,403 shares of Class A Common Stock on August 12, 2026. The sale was executed at a weighted average price of $17.51 per share, with individual trade prices ranging from $17.40 to $17.67 per share. Following this transaction, Shah directly holds 253,390 shares of Amneal Class A Common Stock.
Amneal Pharmaceuticals, Inc. executive Jason B. Daly, EVP and Chief Legal Officer, reported selling a total of 216,613 shares of Class A Common Stock in two open-market or private transactions. On 2026-08-12 he sold 210,000 shares at $17.40 per share (weighted average, with individual trades between $17.25 and $17.67). On 2026-08-11 he sold 6,613 shares at $17.70 per share (weighted average, with individual trades between $17.65 and $17.73). The Rule 10b5-1 checkbox was not marked as being pursuant to a trading plan, and post-transaction share holdings were not reported in this form.
BUCHI J KEVIN reported disposition transactions in this Form 4 filing.
Amneal Pharmaceuticals, Inc. director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on 2026-08-11 at a weighted average price of $17.18 per share. According to the footnote, the shares were sold in multiple trades between $17.07 and $17.31 per share. Following this activity, 93,499 shares are held indirectly by a trust and a separate holding entry shows 75,077 shares held directly.
AMRX filed a notice of proposed sale of up to 50,000 shares of common stock, to be sold through Merrill Lynch at 157 Church St., New Haven, CT, with a notation of NASDAQ as the trading market. The filing also lists prior transactions over the past three months related to equity compensation.
Amneal Pharmaceuticals, Inc. reported that reporting person Tushar Bhikhubhai Patel, a greater-than-10% owner, indirectly acquired 12,763,469 shares of Amneal Class A common stock. The shares are held through limited liability companies controlled by family trusts.
The acquisition occurred on August 10, 2026 as part of Amneal’s purchase of 100% of Kashiv BioSciences, LLC membership interests. Deal consideration included $375,000,000 in cash (subject to purchase price adjustments) and 28,942,098 Amneal Class A shares. Following this transaction, entities associated with Patel held 61,341,678 Class A shares indirectly.
Tushar Patel filed Amendment No. 6 reporting his beneficial ownership of Amneal Pharmaceuticals Class A common stock. He beneficially owns 61,341,678 shares, representing 17.6% of the Class A common stock outstanding, with sole voting and dispositive power over all of these shares.
The ownership percentage is based on 348,296,017 shares of Class A common stock outstanding as of August 10, 2026 plus 28,942,098 shares issued in connection with Amneal’s acquisition of Kashiv BioSciences. As part of this transaction, Amneal Pharmaceuticals LLC agreed to pay the Kashiv sellers an aggregate of $375,000,000 in cash, subject to adjustments, and Amneal was required to issue an aggregate of 28,942,098 Amneal Class A shares to the sellers, including Rock Nola, LLC. Rock Nola, whose sole member is a trust controlled by Patel, received 12,763,469 shares, contributing to Patel’s reported beneficial ownership, which also includes shares held by TI SIE 2.